Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Treatment‐Effect Heterogeneity and a Simple Framework for Estimating Survival Benefit Associated With Local Therapy in Nonmetastatic Advanced Prostate Cancer: A Multicenter KAMU ‐ ON Cohort Study. Local targets link to admitted publications; unresolved targets remain external evidence.
Recent Advances in the Management of High‐Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions
2020 · External reference
Treatment and Staging Intensification Strategies Associated With Radical Prostatectomy for High‐Risk Prostate Cancer: Efficacy Evaluation and Exploration of Novel Approaches
10.3390/cancers16132465 · 2024 · External reference
Benefits and Risks of Primary Treatments for High‐Risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
10.1016/j.eururo.2020.01.033 · 2020 · External reference
Combination Therapies in Locally Advanced and Metastatic Hormone‐Sensitive Prostate Cancer
10.1016/j.eururo.2025.01.010 · 2025 · External reference
Investigating the Latest Evidence From Phase III Trials Supporting Treatment Options for De Novo Clinically Lymph Node‐Positive Hormone‐Sensitive Prostate Cancer
10.1007/s11912-025-01665-3 · 2025 · External reference
Narrative Review of Management Strategies and Outcomes in Node‐Positive Prostate Cancer
10.21037/tau-20-1031 · 2021 · External reference
Surgical Management and Considerations for Patients With Localized High‐Risk Prostate Cancer
10.1007/s11864-023-01162-4 · 2024 · External reference
Prostate Radiotherapy for Metastatic Hormone‐Sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta‐Analysis
10.1016/j.eururo.2019.02.003 · 2019 · External reference
Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial
10.1016/s0140-6736(18)32486-3 · 2018 · External reference
Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined With Concurrent Radiation Therapy to the Prostate in Patients With Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data From the HORRAD Trial
10.1016/j.eururo.2018.09.008 · 2019 · External reference
Impact of Prostate Radiotherapy on Survival Outcomes in Clinically Node‐Positive Prostate Cancer: A Multicentre Retrospective Analysis
10.1016/j.radonc.2023.109746 · 2023 · External reference
Local Therapy on Clinically Lymph Node‐Positive Prostate Cancer: A Systematic Review and Meta‐Analysis
10.1016/j.euo.2023.09.002 · 2024 · External reference
The Predictive Approaches to Treatment Effect Heterogeneity (PATH) Statement
10.7326/m18-3667 · 2020 · External reference
The Predictive Approaches to Treatment Effect Heterogeneity (PATH) Statement: Explanation and Elaboration
10.7326/m18-3668 · 2020 · External reference
The Emerging Relevance of Heterogeneity of Treatment Effect in Clinical Care: A Study Using Stage IV Prostate Cancer as a Model
10.2217/cer.13.70 · 2013 · External reference
Stage‐Specific Temporal Trends in Treatment Patterns and Overall Survival in Prostate Cancer: A Multicentre Real‐World Cohort Study From KAMU‐ON
10.1111/iju.70617 · 2026 · External reference
Combination of Androgen Deprivation Therapy With Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial
10.1016/j.euo.2022.06.001 · 2022 · External reference
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men With Metastatic De Novo Hormone‐Sensitive Prostate Cancer in Trials Investigating Docetaxel (The STOPCAP Collaboration)
10.1016/j.euf.2026.02.001 · 2026 · External reference
Comparative Performance and External Validation of the Multivariable PREDICT Prostate Tool for Non‐Metastatic Prostate Cancer: A Study in 69,206 Men From Prostate Cancer Data Base Sweden (PCBaSe)
10.1186/s12916-020-01606-w · 2020 · External reference
Individual Prognosis at Diagnosis in Nonmetastatic Prostate Cancer: Development and External Validation of the PREDICT Prostate Multivariable Model
10.1371/journal.pmed.1002758 · 2019 · External reference
Clinical Impact of the Predict Prostate Risk Communication Tool in Men Newly Diagnosed With Nonmetastatic Prostate Cancer: A Multicentre Randomised Controlled Trial
10.1016/j.eururo.2021.08.001 · 2021 · External reference
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long‐Term Hormonal Therapy and Radiotherapy in Men With High‐Risk Prostate Cancer Across Multiple Phase III Trials
10.1200/jco.24.00365 · 2025 · External reference
A Computational Pathology Model to Predict Docetaxel Benefit in Localized High‐Risk and Metastatic Prostate Cancer
10.1158/1078-0432.ccr-25-3327 · 2026 · External reference
Using the Cell‐Cycle Risk Score to Predict the Benefit of Androgen‐Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer
10.1200/po.23.00722 · 2024 · External reference
